Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510077 | 0.85 | KDM4E (0.56) | FLT3HRH4CNR2 | |
| SCHEMBL8267069 | 0.84 | FLT3 (0.45) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL29988822 | 0.83 | CNR2 (0.65) | FLT3PDGFRBPDGFRAHRH4CNR2 | |
| SCHEMBL5507170 | 0.83 | PDGFRB (0.62) | FLT3PDGFRBPDGFRAHRH4 | |
| SCHEMBL5505370 | 0.82 | CNR2 (0.43) | CNR2 | |
| SCHEMBL5508084 | 0.78 | KDM4E (0.66) | FLT3PDGFRBPDGFRACNR2MAPT | |
| SCHEMBL5508886 | 0.77 | FLT3 (0.48) | FLT3CNR2 | |
| SCHEMBL2230377 | 0.73 | FLT3 (1.00) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL61386 | 0.72 | SMAD3 (1.00) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL2732420 | 0.71 | FLT3 (0.73) | FLT3PDGFRBKITABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | claimed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | claimed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | claimed |
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | FLT3 3256/4885PDGFRB 2665/4885KIT 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.